Bioabsorbable Stenting for Peripheral Arterial Occlusive Disease

Perspectives in Vascular Surgery and Endovascular Therapy

Volumn 18, Issue 4, 2006, Pages 295-298

  Geraghty, Patrick J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

absorbable implant; hyperplasia; lactic acid; magnesium; stent

Indexed keywords

BIODEGRADABLE IMPLANT; BLOOD VESSEL TRANSPLANTATION; HUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PERIPHERAL VASCULAR DISEASE; PROSTHESIS; REVIEW; STENT;

ABSORBABLE IMPLANTS; ARTERIAL OCCLUSIVE DISEASES; BLOOD VESSEL PROSTHESIS IMPLANTATION; HUMANS; PERIPHERAL VASCULAR DISEASES; PROSTHESIS DESIGN; STENTS;

EID: 34347262104     PISSN: 15310035     EISSN: None     Source Type: Journal    
DOI: 10.1177/1531003506297195     Document Type: Article

References (26)

1. Dotter C.T., Judkins MP. Percutaneous transluminal treatment of arteriosclerotic obstruction. Radiology. 1965; 84: 631-643.
2. Dotter C.T., Krippaehne W.W., Judkins MP. Transluminal recanalization and dilatation in atherosclerotic obstruction of femoral popliteal system. Am Surg. 1965;31: 453-459.
3. Dotter CT. Transluminally-placed coilspring endarterial tube grafts. Long-term patency in canine popliteal artery. Invest Radiol. 1969;4: 329-332.
4. Gruentzig AR. Percutaneous transluminal coronary angioplasty. Semin Roentgenol. 1981;16: 152-153.
5. Mintz G.S., Popma J.J., Pichard A.D., et al. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation. 1996;94: 35-43.
6. Palmaz J.C., Richter G.M., Noldge G, Kauffmann G.W., Wenz W. [Intraluminal Palmaz stent implantation. The first clinical case report on a balloon-expanded vascular prosthesis]. Radiologe.1987;27: 560-563.
7. Bertrand M.E., Rupprecht H.J., Urban P, Gershlick AH. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation. 2000;102: 624-629.
8. Steinhubl S.R., Berger P.B., Mann JT 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288: 2411-2420.
9. Hoffmann R, Mintz G.S., Dussaillant G.R., et al. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation. 1996;94: 1247-1254.
10. Grube E, Silber S, Hauptmann K.E., et al. TAXUS I: sixand twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation. 2003;107: 38-42.
11. Morice M.C., Serruys P.W., Sousa J.E., et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346: 1773-1780.
12. McFadden E.P., Stabile E, Regar E, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004;364: 1519-1521.
13. Spertus J.A., Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation. 2006;113: 2803-2809.
14. Kotani J, Awata M, Nanto S, et al. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol. 2006;47: 2108-2111.
15. Yadav J.S., Wholey M.H., Kuntz R.E., et al. Protected carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med. 2004;351: 1493-1501.
16. Willfort-Ehringer A, Ahmadi R, Gschwandtner M.E., Haumer M, Lang W, Minar E. Single-center experience with carotid stent restenosis. J Endovasc Ther. 2002;9: 299-307.
17. Schillinger M, Sabeti S, Loewe C, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006;354: 1879-1888.
18. Mewissen MW. Self-expanding nitinol stents in the femoropopliteal segment: technique and mid-term results. Tech Vasc Interv Radiol. 2004;7: 2-5.
19. Scheinert D, Scheinert S, Sax J, et al. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol. 2005;45: 312-315.
20. Duda S.H., Bosiers M, Lammer J, et al. Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial. J Vasc Interv Radiol. 2005;16(3): 331-338.
21. Duda S.H., Pusich B, Richter G, et al. Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: six-month results. Circulation. 2002;106: 1505-1509.
22. Tamai H, Igaki K, Kyo E, et al. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation. 2000;102: 399-404.
23. Biamino G, Schmidt A, Scheinert D. Treatment of SFA lesions with PLLA biodegradable stents: results of the PERSEUS study. J Endovasc Ther. 2005;12(Suppl I): 5-5.
24. Heublein B, Rohde R, Kaese V, Niemeyer M, Hartung W, Haverich A. Biocorrosion of magnesium alloys: a new principle in cardiovascular implant technology? Heart. 2003;89: 651-656.
25. Eggebrecht H, Rodermann J, Hunold P, et al. Images in cardiovascular medicine. Novel magnetic resonance-compatible coronary stent: the absorbable magnesium-alloy stent. Circulation. 2005;112: e303-e304.
26. Peeters P, Bosiers M, Verbist J, Deloose K, Heublein B. Preliminary results after application of absorbable metal stents in patients with critical limb ischemia. J Endovasc Ther. 2005;12: 1-5.